is semaglutide a controlled drug Nursing homes weigh pros, cons of new weight loss drugs as limited Medicare coverage kicks in GLP-1 drugs such as semaglutide

Bioavailability Emphasis on forms that deliver active glutathione to cells, favoring liposomal, S-acetyl, and branded options

doi: 10.1186/s13098-025-02045-4 175 KongXZhaoYWangXYuYMengYYanGet al

For years, healthcare providers, compounders, researchers, and patients have operated in an environment of uncertainty surrounding peptide therapies

Our work shows GLP-1 adoption + further penetration is behind a mega-trend that can drive robust demand in US apparel (esp in cats sensitive to sizing) for multiple years. Wells Fargo estimates that GLP-1 has driven a 100 basis-point lift to the apparel categorys growth in 2024 and 120bps in 2025 and has the potential to drive an incremental 160bps to 2026, 170bps to 2027 and 30bps to 2028E

For instance, 15.8% of people taking a 0.5 mg injection experienced nausea, compared to 20.3% of people taking a 1.0 mg injection in clinical trials

Skinny is not necessarily healthy